Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/48283
Title: Integrated guidance to enhance the care of children and adolescents with familial hypercholesterolaemia: Practical advice for the community clinician.
Authors: Horton A.E. ;Martin A.C.;Srinivasan S.;Justo R.N.;Poplawski N.K.;Sullivan D.;Brett T.;Chow C.K.;Nicholls S.J.;Pang J.;Watts G.F.
Monash Health Department(s): Cardiology (MonashHeart)
Institution: (Horton, Nicholls) Monash Heart and Monash Children's Hospital, Monash Health, Melbourne, VIC, Australia (Horton, Nicholls) Monash Cardiovascular Research Centre, Victorian Heart Institute, Monash University, Melbourne, VIC, Australia (Horton) Department of Paediatrics, Monash University, Melbourne, VIC, Australia (Martin) Department General Paediatrics, Perth Children's Hospital, Perth, WA, Australia (Martin) Division of Paediatrics, Faculty of Health and Medical Sciences, University of Western Australia, Perth, WA, Australia (Srinivasan) Institute of Endocrinology and Diabetes, The Children's Hospital at Westmead, Sydney, NSW, Australia (Srinivasan) Discipline of Child and Adolescent Health, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia (Justo) Department of Paediatric Cardiology, Queensland Children's Hospital, Brisbane, QLD, Australia (Justo) School of Medicine, University of Queensland, Brisbane, QLD, Australia (Poplawski) Adult Genetics Unit, Royal Adelaide Hospital, Adelaide, SA, Australia (Poplawski) Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia (Sullivan) Department of Chemical Pathology, Royal Prince Alfred Hospital, Sydney, NSW, Australia (Sullivan) Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia (Brett) General Practice and Primary Health Care Research, School of Medicine, University of Notre Dame Australia, Fremantle, WA, Australia (Chow) Westmead Applied Research Centre, The University of Sydney, Sydney, NSW, Australia (Chow) Department of Cardiology, Westmead Hospital, Sydney, NSW, Australia (Chow) Cardiovascular Division, George Institute for Global Health, Sydney, NSW, Australia (Pang, Watts) School of Medicine, Faculty of Health and Medical Sciences, University of Western Australia, Perth, WA, Australia (Watts) Lipid Disorders Clinic, Cardiometabolic Service, Department of Cardiology, Royal Perth Hospital, Perth, WA, Australia (Watts) Lipid Disorders Clinic, Cardiometabolic Service, Department of Internal Medicine, Royal Perth Hospital, Perth, WA, Australia
Issue Date: 20-Jul-2022
Copyright year: 2022
Publisher: John Wiley and Sons Inc
Place of publication: Australia
Publication information: Journal of Paediatrics and Child Health. 58(8) (pp 1297-1312), 2022. Date of Publication: August 2022.
Journal: Journal of Paediatrics and Child Health
Abstract: Familial hypercholesterolaemia (FH) is a highly penetrant monogenic disorder present from birth that markedly elevates plasma low-density lipoprotein (LDL)-cholesterol (LDL-C) concentration and, if untreated, leads to premature atherosclerosis and coronary artery disease (CAD). At a prevalence of 1:250 individuals, with over 90% undiagnosed, recent estimates suggest that there are approximately 22 000 children and adolescents with FH in Australia and New Zealand. However, the overwhelming majority remain undetected and inadequately treated until adulthood or after their first cardiac event. The guidance in this paper aims to increase awareness about paediatric FH and provide practical advice for the diagnosis and management of FH in children and adolescents. Recommendations are given on the detection, diagnosis, assessment and management of FH in children and adolescents. Recommendations are also made on genetic testing, including counselling and the potential for universal screening programmes. Practical guidance on management includes treatment of non-cholesterol risk factors, and safe and appropriate use of LDL-C lowering therapies, including statins, ezetimibe, PCSK9 inhibitors and lipoprotein apheresis. Models of care for FH need to be adapted to local and regional health care needs and available resources. Targeting the detection of FH as a priority in children and young adults has the potential to alter the natural history of atherosclerotic cardiovascular disease and recognise the promise of early detection for improving long-term health outcomes. A comprehensive implementation strategy, informed by further research, including assessments of cost-benefit, will be required to ensure that this new guidance benefits all families with or at risk of FH.Copyright © 2022 The Authors. Journal of Paediatrics and Child Health published by John Wiley & Sons Australia, Ltd on behalf of Paediatrics and Child Health Division (The Royal Australasian College of Physicians).
DOI: http://monash.idm.oclc.org/login?url=http://acs.hcn.com.au/?acc=36265&url=https://dx.doi.org/10.1111/jpc.16096
PubMed URL: 35837752 [https://www.ncbi.nlm.nih.gov/pubmed/?term=35837752]
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/48283
Type: Article
Subjects: cardiovascular disease
coronary artery atherosclerosis
cost benefit analysis
counseling
familial hypercholesterolemia
genetic screening
health care need
lipoprotein apheresis
pediatrics
ezetimibe
hydroxymethylglutaryl coenzyme A reductase inhibitor
low density lipoprotein cholesterol
PCSK9 inhibitor
Appears in Collections:Articles

Show full item record

Page view(s)

20
checked on May 18, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.